As production of sustained therapeutic levels of fVIII remains a critical barrier to clinical gene therapy of hemophilia A and no recent transformational advances have been made in the areas of vector manufacturing or potency, transgene engineering approaches, such as ET3, may provide the key innovation necessary to achieve clinical success. The gene discussed is EDN3; the disease is hemophilia A.